Ultrasonic propulsion device clears chronic residual stone fragmentsSeptember 13th 2021
"The device is noninvasive and used in awake subjects. This case demonstrates that even chronic fragments can be successfully cleared, sometimes within hours of the procedure, even if they have not previously cleared for months,” said Mathew Sorensen, MD.
How has the COVID-19 pandemic impacted the delivery of urologic care in the United States?September 6th 2021
“We found that the elderly, female, and patients with Medicaid insurance had the highest decreases in outpatient visits, and among the lowest magnitude recovery compared to pre-pandemic levels," the authors wrote.
PSMA targeted CAR T-cell therapy shows antitumor activity in mCRPCSeptember 1st 2021
"This is the first time that I have seen such impressive responses with an immunotherapy product. The responses of my patients in the trial are far beyond my expectations," said study investigator Susan F. Slovin, MD, PhD.
FDA grants full approval to pembrolizumab in frontline bladder cancerAugust 31st 2021
The FDA has converted the accelerated approval of frontline pembrolizumab in advanced bladder cancer to a full approval and revised the indication to cover the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy.
Novel blood test enhances prostate cancer screeningAugust 18th 2021
Combining the Stockholm3 blood test with MRI-guided prostate biopsy reduced the number of MRIs performed and lowered overdetection, while not sacrificing the capacity to identify clinically significant tumors, according to findings from the STHLM3-MRI study.
Real-world data show clinical utility of novel genomic test in early-stage prostate cancerJuly 30th 2021
Decipher Prostate Biopsy, a 22-gene microarray-based genomic classifier, showed potential as a tool to help guide decisions between active surveillance and radical treatment in men with localized prostate cancer.